Ligand Pharma (LGND) Stock Target Raised After XOMA Acquisition

Bank of America (BofA) has raised its price target for Ligand Pharmaceuticals (LGND) following the company's acquisition of XOMA Corporation. This move reflects confidence in the combined entity's potential to enhance market presence. No specific new price target was provided in the announcement. The acquisition is expected to have a positive impact on Ligand's growth trajectory, which may influence investor sentiment and market performance moving forward.